3 Fantastic Growth Stocks to Buy in August
7
3
BTCCSquare news:
Eli Lilly's recent earnings report triggered a sell-off despite strong revenue growth fueled by its GLP-1 drugs. The stock dipped 19% year-to-date after its weight-loss pill, orforglipron, showed a 12% weight reduction in trials—falling short of the anticipated 15%. Yet, with $28 billion in first-half sales, the company remains a formidable player in healthcare.
Vertex Pharmaceuticals and Summit Therapeutics round out the trio of growth stocks highlighted this month. Vertex continues to dominate the cystic fibrosis market, while Summit's innovative oncology pipeline attracts speculative interest. Both stocks present compelling opportunities amid August's market volatility.
By:
